皰疹病毒感染類(lèi)疾病高發(fā),可形成終生感染,給人類(lèi)健康和財(cái)產(chǎn)安全帶來(lái)了極大的損失。然而,臨床上批準(zhǔn)常用的治療皰疹病毒感染的藥物僅幾種核苷類(lèi)似物,這些藥物的應(yīng)用往往還會(huì)引發(fā)耐藥性和不良反應(yīng)。因而,克服抗皰疹病毒藥物存在的問(wèn)題,探索新型的抗皰疹病毒藥物迫在眉睫?？偨Y(jié)了臨床常用抗皰疹病毒感染藥物、靶向病原體的抗皰疹病毒抑制劑和靶向宿主的抗皰疹病毒抑制劑,介紹了聯(lián)合用藥抗病毒新型策略,以期為科研人員在抗皰疹病毒藥物方面的研究提供參考。

The high incidence of herpesvirus infection can lead to life-long infection, which brings great loss to human health and property safety. Only few nucleoside analog drugs are approved for the treatment of herpesvirus infections, and long-term use of these drugs often leads to drug resistance and adverse action. Overcoming the problems of anti-herpesvirus drugs and exploring new types of anti-herpesvirus drugs is urgent. This article summarizes commonly used anti-herpesvirus infection drugs in clinical practice, anti-herpesvirus inhibitors targeting pathogens, anti-herpesvirus inhibitors targeting hosts, and new strategies for combination therapy of antiviral drugs, hoping to provide reference for researchers in the research of anti-herpesvirus drugs.

R978.7